Criteria to define response to therapy in paediatric rheumatic diseases

European Journal of Clinical Pharmacology

Volumn 67, Issue SUPPL. 1, 2011, Pages

  Ruperto, Nicolino ^a   Pistorio, Angela ^a   Ravelli, Angelo ^b   Hasija, Rachana ^a   Guseinova, Dinara ^a   Filocamo, Giovanni ^a   Demirkaya, Erkan ^a   Malattia, Clara ^a   Martini, Alberto ^a,b  

^a G GASLINI INSTITUTE   (Italy)

^b UNIVERSITY OF GENOA   (Italy)

Author keywords

Clinical trials; Juvenile dermatomyositis; Juvenile idiopathic arthritis; Juvenile systemic lupus erythematosus; Response to therapy

Indexed keywords

CLINICAL ASSESSMENT; CLINICAL ASSESSMENT TOOL; CLINICAL PRACTICE; CLINICAL PROTOCOL; CONSENSUS DEVELOPMENT; DERMATOMYOSITIS; DISEASE EXACERBATION; EVIDENCE BASED MEDICINE; HUMAN; JOINT FUNCTION; JUVENILE RHEUMATOID ARTHRITIS; OUTCOME ASSESSMENT; PATIENT SELECTION; PRIORITY JOURNAL; QUALITY OF LIFE; REMISSION; REVIEW; SYSTEMIC LUPUS ERYTHEMATOSUS; TREATMENT RESPONSE; VALIDATION PROCESS;

CHILD; CLINICAL TRIALS AS TOPIC; ENDPOINT DETERMINATION; HUMANS; INTERNATIONAL COOPERATION; PEDIATRICS; PROSPECTIVE STUDIES; RHEUMATIC DISEASES; TREATMENT OUTCOME;

EID: 79955576140     PISSN: 00316970     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00228-010-0937-8     Document Type: Review

References (48)

1. Food and Drug Administration (FDA) (1998) Regulations requiring manufacturers to assess the safety and effectiveness of new drugs and biologic products in pediatrics patients (21 CFR Parts 201, 312, 314, and 601). Fed Regist 63(231)
2. Regulation (EC) (2006) no 1901/2006 of the European Parliament and of the Council of 12 December 2006 on medicinal products for paediatric use and amending Regulation (EEC) No 1768/92, Directive 2001/20/EC, Directive 2001/83/EC and Regulation (EC) No 726/2004. Off J Eur Union L 378:1-19
3. Connor JD (1999) A look at the future of pediatric therapeutics: an investigator's perspective of the new pediatric rule. Pediatrics 104(3):610-613
4. Ruperto N, Martini A, for the Paediatric Rheumatology International Trials Organization (PRINTO) (2000) Use of unlabelled and off licence drugs in children. A European paediatric rule is needed to protect children. Br Med J 320(7243):1210-1211 (Pubitemid 30224281)
5. Ruperto N, Martini A (2004) International research networks in pediatric rheumatology: the PRINTO perspective. Curr Opin Rheumatol 16(5):566-570 (Pubitemid 39128326)
6. Ruperto N, Meiorin S, Iusan SM et al (2008) Consensus procedures and their role in pediatric rheumatology. Curr Rheumatol Rep 10(2):142-146
7. Delbecq AL, Van de Ven AH, Gustafson DH (1975) Group techniques for program planning. A guide to nominal group and Delphi processes. Scott Foresman and Co, Glenview
8. Sniderman AD (1999) Clinical trials, consensus conferences, and clinical practice. Lancet 354(9175):327-330
9. Giannini EH, Ruperto N, Ravelli A et al (1997) Preliminary definition of improvement in juvenile arthritis. Arthritis Rheum 40(7):1202-1209 (Pubitemid 27430130)
10. Ruperto N, Ravelli A, Falcini F et al (1998) Performance of the preliminary definition of improvement in juvenile chronic arthritis patients treated with methotrexate. Ann Rheum Dis 57(1):38-41 (Pubitemid 28175218)
11. Felson DT, Anderson JJ, Boers M et al (1995) American College of Rheumatology preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum 38:727-735
12. Strand V, Gladman D, Isenberg D et al (1999) Outcome measures to be used in clinical trials in systemic lupus erythematosus. J Rheumatol 26(2):490-497 (Pubitemid 29066763)
13. Smolen JS, Strand V, Cardiel M et al (1999) Randomized clinical trials and longitudinal observational studies in systemic lupus erythematosus: consensus on a preliminary core set of outcome domains. J Rheumatol 26(2):504-507 (Pubitemid 29066766)
14. Rider LG, Giannini EH, Harris-Love M et al (2003) Defining clinical improvement in adult and juvenile myositis. J Rheumatol 30(3):603-617 (Pubitemid 36301957)
15. Rider LG, Giannini EH, Brunner HI et al (2004) International consensus on preliminary definitions of improvement in adult and juvenile myositis. Arthritis Rheum 50(7):2281-2290 (Pubitemid 38924407)
16. Oddis CV, Rider LG, Reed AM et al (2005) International consensus guidelines for trials of therapies in the idiopathic inflammatory myopathies. Arthritis Rheum 52(9):2607-2615 (Pubitemid 41369088)
17. Ruperto N, Ravelli A, Murray KJ et al (2003) Preliminary core sets of measures for disease activity and damage assessment in juvenile systemic lupus erythematosus and juvenile dermatomyositis. Rheumatol Oxf 42(12):1452-1459 (Pubitemid 37508918)
18. Ruperto N, Ravelli A, Cuttica R et al (2005) The Pediatric Rheumatology International Trials Organization criteria for the evaluation of response to therapy in juvenile systemic lupus erythematosus: prospective validation of the disease activity core set. Arthritis Rheum 52(9):2854-2864 (Pubitemid 41369116)
19. Ruperto N, Ravelli A, Oliveira S et al (2006) The Pediatric Rheumatology International Trials Organization/American College of Rheumatology provisional criteria for the evaluation of response to therapy in juvenile systemic lupus erythematosus. Prospective validation of the definition of improvement. Arthritis Rheum 55(3):355-363 (Pubitemid 43887020)
20. Ruperto N, Ravelli A, Pistorio A et al (2008) The provisional Pediatric Rheumatology International Trial Organization/American College of Rheumatology/European League Against Rheumatism disease activity core set for the evaluation of response to therapy in juvenile dermatomyositis: a prospective validation study. Arthritis Rheum 59(1):4-13 (Pubitemid 351171873)
21. Boers M, Brooks P, Strand CV, Tugwell P (1998) The OMERACT filter for outcome measures in rheumatology. J Rheumatol 25(2):198-199
22. Bellamy N (1999) Clinimetric concepts in outcome assessment: the OMERACT filter. J Rheumatol 26(4):948-950
23. Liang MH, Fossel AH, Larson MG (1990) Comparisons of five health status instruments for orthopedic evaluation. Med Care 28(7):632-642
24. Cronbach LJ (1951) Coefficient alfa and the internal structure of tests. Psychometrika 16:297-334
25. Filocamo G, Davì S, Pistorio A et al (2010) Comparison of 21-numbered circle and 10-centimeter horizontal line visual analog scales for physician's and parent's subjective ratings in juvenile idiopathic arthritis. J Rheumatol 37:1534-1541
26. Singh G, Athreya BH, Fries JF, Goldsmith DP (1994) Measurement of health status in children with juvenile rheumatoid arthritis. Arthritis Rheum 37:1761-1769 (Pubitemid 24371878)
27. Martini A, Ruperto N, for the Paediatric Rheumatology International Trials Organization (PRINTO) (Guest eds) (2001) Quality of life in juvenile idiopathic arthritis patients compared to healthy children. Clin Exp Rheumatol 19[Suppl. 23]:S1-S172
28. Ruperto N, Ravelli A, Pistorio A et al (2001) Cross-cultural adaptation and psychometric evaluation of the Childhood Health Assessment Questionnaire (CHAQ) and the Child Health Questionnaire (CHQ) in 32 countries. Review of the general methodology. Clin Exp Rheumatol 19(4):S1-S9 (Pubitemid 33730178)
29. Filocamo G, Sztajnbok F, Cespedes-Cruz A et al (2007) Development and validation of a new short and simple measure of physical function for juvenile idiopathic arthritis. Arthritis Rheum 57(6):913-920 (Pubitemid 47237316)
30. Landgraf JM, Abetz L, Ware JE (1996) The CHQ user's manual, 1st edn. The Health Institute, New England Medical Center, Boston
31. Filocamo G, Schiappapietra B, Bertamino M et al (2010) A new short and simple health-related quality of life measure for paediatric rheumatic diseases: initial validation in juvenile idiopathic arthritis. Rheumatology 49:1272-1280
32. Cassidy JT, Levinson JE, Bass JC et al (1986) A study of classification criteria for a diagnosis of juvenile rheumatoid arthritis. Arthritis Rheum 29:274-281 (Pubitemid 17022828)
33. Ruperto N, Giannini EH (1996) Redundancy of conventional articular response variables used in juvenile chronic arthritis clinical trials. Ann Rheum Dis 55:73-75
34. Ravelli A, Viola S, Ruperto N et al (1997) Correlation between conventional disease activity measures in juvenile chronic arthritis. Ann Rheum Dis 56(3):197-200 (Pubitemid 27144207)
35. Bazso A, Consolaro A, Ruperto N et al (2009) Development and testing of reduced joint counts in juvenile idiopathic arthritis. J Rheumatol 36(1):183-190
36. Bombardier C, Gladman DD, Urowitz MB, Caron D, Chang CH (1992) Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE. Arthritis Rheum 35(6):630-640
37. Liang MH, Socher SA, Larson MG, Schur PH (1989) Reliability and validity of six systems for the clinical assessment of disease activity in systemic lupus erythematosus. Arthritis Rheum 32:1107-1118 (Pubitemid 19237865)
38. Vitali C, Bencivelli W, Isenberg DA et al (1992) Disease activity in systemic lupus erythematosus: report of the Consensus Study Group of the European Workshop for Rheumatology Research. II. Identification of the variables indicative of disease activity and their use in the development of an activity score. Clin Exp Rheumatol 10:541-547
39. Vitali C, Bencivelli W, Mosca M et al (1999) Development of a clinical chart to compute different disease activity indices for systemic lupus erythematosus. J Rheumatol 26(2):498-501 (Pubitemid 29066764)
40. Lovell DJ, Lindsley CB, Rennebohm RM et al (1999) Development of validated disease activity and damage indices for the juvenile idiopathic inflammatory myopathies - II. The Childhood Myositis Assessment Scale (CMAS): a quantitative tool for the evaluation of muscle function. Arthritis Rheum 42(10):2213-2219
41. Rennebohm RM, Jones K, Huber AM et al (2004) Normal scores for nine maneuvers of the childhood myositis assessment scale. Arthritis Rheum Arthritis Care Res 51(3):365-370 (Pubitemid 38725134)
42. Huber AM, Feldman BM, Rennebohm RM et al (2004) Validation and clinical significance of the childhood myositis assessment scale for assessment of muscle function in the juvenile idiopathic inflammatory myopathies. Arthritis Rheum 50(5):1595-1603 (Pubitemid 38608082)
43. Hicks J, Wesley R, Koziol D et al (2000) Validation of manual muscle testing (MMT) in the assessment of juvenile dermatomyositis (JDM). Arthritis Rheum 43[Suppl]:S194
44. Bode RK, Klein-Gitelman MS, Miller ML, Lechman TS, Pachman LM (2003) Disease activity score for children with juvenile dermatomyositis: reliability and validity evidence. Arthritis Rheum Arthritis Care Res 49(1):7-15 (Pubitemid 36286124)
45. Isenberg DA, Allen E, Farewell V et al (2004) International consensus outcome measures for patients with idiopathic inflammatory myopathies. Development and initial validation of myositis activity and damage indices in patients with adult onset disease. Rheumatology 43(1):49-54
46. Giannini EH, Lovell DJ, Silverman ED et al (1996) Intravenous immunoglobulin in the treatment of polyarticular juvenile rheumatoid arthritis: a phase I/II study. J Rheumatol 23(5):919-924 (Pubitemid 26160254)
47. Brunner HI, Lovell DJ, Finck BK, Giannini EH (2002) Preliminary definition of disease flare in juvenile rheumatoid arthritis. J Rheumatol 29(5):1058-1064 (Pubitemid 34493514)
48. Wallace CA, Ruperto N, Giannini E et al (2004) Preliminary criteria for clinical remission for select categories of juvenile idiopathic arthritis. J Rheumatol 31(11):2290-2294 (Pubitemid 39453253)